Biolexis Therapeutics, an American Fork-based clinical-stage AI-enabled drug discovery company, has announced the launch of a new subsidiary called Metabolexis, a new pipeline company developing drugs for the treatment of obesity and Type 2 diabetes. The company said the new medications will have the potential to improve human longevity.
“We believe that our novel small molecule therapeutics delivered orally can address some of the toxicity and delivery complications associated with today’s treatments,” said Dr. David J. Bearss, CEO and co-founder of Biolexis Therapeutics. “With the launch of Metabolexis, we have an opportunity to address this immense need by providing clinically effective, easily administered and economically viable treatments that improve the lives of these patients.”
Metabolexis said it intends to file investigational new drug applications (INDs) for three under-development agents by the end of the fourth quarter 2024 and to initiate first-in-human Phase I safety clinical trials in the first quarter of 2025. Utilizing its MolecuLern process, the company has identified lead candidates currently in pre-clinical development.
“Obesity-related conditions, including Type 2 Diabetes, cardiometabolic, stroke, and age-related diseases, continue to be crucial issues in our communities,” said Dr. Hariprasad Vankayalapati, chief science officer and co-founder of Biolexis Therapeutics. “As we continue to research, develop and implement innovative methods to address critical unmet medical needs, we believe our work … will expand treatment options for patients with these and other metabolic disorders.”